https://doi.org/10.5217/ir.2023.00043 • Intest Res 2024;22(2):172-185

Supplementary Table 2. Primary and Major Secondary Outcomes and Definitions for LUCENT-1 and LUCENT-2

Study	Endpoint	Definition
LUCENT-1 Primary endpoint[a]	Clinical remission at wk 12	Clinical remission is based on the MMS and defined as: SF = 0 or SF = 1 with a ≥ 1-point decrease from baseline; RB = 0; and ES = 0 or 1 (excluding friability)
LUCENT-1 Major secondary endpoints[a]	Alternate clinical remission at wk 12	SF = 0 or 1; RB = 0; ES = 0 or 1 (excluding friability)
	Clinical response at wk 12	Based on MMS and defined as: ≥ 2-point and ≥ 30% decrease in the MMS from baseline; RB = 0 or 1, or ≥ 1-point decrease from baseline
	Endoscopic improvement at wk 12	ES = 0 or 1 (excluding friability)
	Symptomatic remission at wk 4	SF = 0 or SF = 1 with ≥ 1-point decrease from baseline;
	Symptomatic remission at wk 12	RB = 0
	Clinical response in the biologic-failed population at wk 12	Based on MMS and defined as: ≥ 2-point and ≥ 30% decrease in the MMS from baseline; RB = 0 or 1, or ≥ 1-point decrease from baseline
	Bowel movement urgency improvement at wk 12	Change from baseline in the urgency NRS
	Histologic-endoscopic mucosal improvement at wk 12	Histologic improvement, defined using Geboes scoring system with neutrophil infiltration in < 5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue; ES = 0 or 1 (excluding friability)
LUCENT-2 Primary endpoint[a]	Clinical remission at wk 40 (wk 52 of continuous therapy) among patients induced into clinical response with mirikizumab in LUCENT-1	Clinical remission at wk 40 defined as: SF = 0 or SF = 1 with a ≥ 1 point decrease from baseline; RB = 0; and ES = 0 or 1 (excluding friability)
LUCENT-2 Major secondary endpoints	Alternate clinical remission at wk 40 among patients induced into clinical response with mirikizumab in LUCENT-1	SF = 0 or 1; RB = 0; ES = 0 or 1 (excluding friability)
	Endoscopic improvement at wk 40 among patients induced into clinical response with mirikizumab in LUCENT-1	ES = 0 or 1 (excluding friability)
	Histologic-endoscopic mucosal improvement plus absence of neutrophils at wk 40 among patients induced into clinical response with mirikizumab in LUCENT-1	Histologic improvement with resolution of mucosal neutrophils, defined using the Geboes scoring system with subscores of 0 for grades: 2b (lamina propria neutrophils); 3 (neutrophils in epithelium); 4 (crypt destruction); 5 (erosion or ulceration); ES = 0 or 1 (excluding friability)
	Bowel movement urgency improvement at wk 40 among patients who were induced into clinical response with mirikizumab in LUCENT-1	Change from induction baseline in the urgency NRS
	Corticosteroid-free remission without surgery among patients induced into clinical response with mirikizumab in LUCENT-1[a]	Clinical remission at wk 40; Symptomatic remission at wk 28; No corticosteroid use for ≥ 12 wk prior to wk 40
	Maintenance of clinical remission at wk 40 (wk 52 of continuous therapy) among patients induced into clinical remission with mirikizumab in LUCENT-1	SF = 0 or SF = 1 with a ≥ 1-point decrease from baseline; RB = 0; ES = 0 or 1 (excluding friability)
	Bowel urgency NRS of 0 or 1 at wk 40 among patients induced into clinical response with mirikizumab in LUCENT-1 and had urgency NRS ≥ 3 at induction baseline	Urgency NRS = 0 or 1

[a]Denominator includes all patients irrespective of baseline corticosteroid use status. All primary and major secondary endpoints were evaluated for mirikizumab versus placebo.
MMS, modified mayo score; SF, stool frequency; RB, rectal bleeding; ES, endoscopic subscore; NRS, numeric rating scale.